Galectin Therapeutics Inc... (GALT)
NASDAQ: GALT
· Real-Time Price · USD
3.57
-0.19 (-5.05%)
At close: Aug 15, 2025, 3:59 PM
3.55
-0.56%
After-hours: Aug 15, 2025, 06:50 PM EDT
Galectin Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | 80K | 80K | 80K | 80K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 19K | 28K | 27K | 35K | 26K | 17K | 16K | 8K | 15K | 25K | 28K | 38K | 41K | 41K | 30K | 20K | 10K |
Gross Profit | -9K | -18K | 53K | 45K | 54K | 63K | -16K | -8K | -15K | -25K | -28K | -38K | -41K | -41K | -30K | -20K | -10K |
Operating Income | -32.78M | -42.43M | -39.57M | -39.67M | -37.38M | -38.07M | -39.14M | -38.1M | -38.76M | -38.35M | -35.14M | -35.27M | -33.8M | -30.18M | -30.59M | -28.27M | -26.18M |
Interest Income | 292K | 337K | 327K | 296K | 266K | 230K | 186K | 142K | 95K | 52K | 22K | 5K | 3K | 3K | 5K | 9K | 17K |
Pretax Income | -45.19M | -47.05M | -45.08M | -44.28M | -41.03M | -41.07M | -41.7M | -39.87M | -40.37M | -38.78M | -35.36M | -35.29M | -34.12M | -30.53M | -31.16M | -28.58M | -26.25M |
Net Income | -45.19M | -47.05M | -45.08M | -44.28M | -41.03M | -41.07M | -41.7M | -39.87M | -40.37M | -38.78M | -35.36M | -35.29M | -34.12M | -30.53M | -31.16M | -28.58M | -26.25M |
Selling & General & Admin | 5.68M | 5.86M | 5.88M | 5.84M | 5.99M | 5.94M | 6.24M | 6.33M | 6.28M | 6.62M | 6.56M | 6.67M | 6.82M | 6.36M | 6.25M | 5.77M | 5.45M |
Research & Development | 35M | 36.57M | 33.69M | 33.83M | 31.39M | 32.13M | 32.91M | 31.77M | 32.48M | 31.74M | 28.59M | 28.6M | 26.98M | 23.82M | 24.33M | 22.5M | 20.73M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 40.68M | 42.43M | 39.57M | 39.67M | 37.38M | 38.07M | 39.14M | 38.1M | 38.76M | 38.35M | 35.14M | 35.27M | 33.8M | 30.18M | 30.59M | 28.27M | 26.18M |
Interest Expense | 6.23M | 5.54M | 4.66M | 4M | 3.38M | 2.79M | 2.25M | 1.69M | 1.27M | 1.03M | 997K | 839K | 695K | 490K | 240K | 151K | 87K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 32.78M | 42.43M | 39.57M | 39.67M | 37.38M | 38.07M | 39.14M | 38.1M | 38.76M | 38.35M | 35.14M | 35.27M | 33.8M | 30.18M | 30.59M | 28.27M | 26.18M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 63.2M | 62.74M | 62.28M | 62.23M | 61.98M | 60.16M | 59.7M | 59.58M | 59.48M | 59.43M | 59.4M | 59.39M | 59.35M | 58.53M | 59.29M | 58.31M | 57.13M |
Shares Outstanding (Diluted) | 63.2M | 62.74M | 62.28M | 62.23M | 61.98M | 60.16M | 59.7M | 59.58M | 59.48M | 59.43M | 59.4M | 59.39M | 59.35M | 58.53M | 59.29M | 58.31M | 57.13M |
EPS (Basic) | -0.72 | -0.76 | -0.73 | -0.79 | -0.74 | -0.74 | -1.09 | -0.99 | -1 | -0.98 | -0.59 | -0.59 | -0.58 | -0.52 | -0.54 | -0.5 | -0.46 |
EPS (Diluted) | -0.72 | -0.76 | -0.73 | -0.79 | -0.74 | -0.74 | -1.09 | -0.99 | -1 | -0.98 | -0.59 | -0.59 | -0.58 | -0.52 | -0.54 | -0.5 | -0.46 |
EBITDA | -31.04M | -41.47M | -40.38M | -40.25M | -37.62M | -38.23M | -39.4M | -38.14M | -39.05M | -37.71M | -34.33M | -34.41M | -33.39M | -30M | -30.88M | -28.39M | -26.12M |
EBIT | -31.07M | -41.51M | -40.41M | -40.28M | -37.64M | -38.27M | -39.45M | -38.19M | -39.1M | -37.74M | -34.37M | -34.45M | -33.43M | -30.04M | -30.92M | -28.43M | -26.16M |
Depreciation & Amortization | 28K | 37K | 36K | 35K | 26K | 49K | 48K | 47K | 54K | 32K | 35K | 38K | 41K | 41K | 39K | 39K | 37K |